Capital Investment Counsel Inc Has $478,000 Stock Position in The Clorox Company (NYSE:CLX)

Capital Investment Counsel Inc lowered its stake in The Clorox Company (NYSE:CLX) by 5.3% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 2,936 shares of the company’s stock after selling 164 shares during the period. Capital Investment Counsel Inc’s holdings in Clorox were worth $478,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of CLX. Innealta Capital LLC acquired a new position in Clorox in the 2nd quarter valued at about $30,000. Trifecta Capital Advisors LLC boosted its holdings in Clorox by 139.8% in the 2nd quarter. Trifecta Capital Advisors LLC now owns 223 shares of the company’s stock valued at $30,000 after purchasing an additional 130 shares during the period. GoalVest Advisory LLC bought a new stake in Clorox in the 1st quarter valued at about $31,000. First Foundation Advisors bought a new stake in Clorox in the 1st quarter valued at about $31,000. Finally, Family Firm Inc. bought a new stake in Clorox in the 2nd quarter valued at about $31,000. Institutional investors and hedge funds own 78.53% of the company’s stock.

Clorox Price Performance

Shares of NYSE:CLX opened at $159.04 on Thursday. The company has a market cap of $19.75 billion, a price-to-earnings ratio of 82.40, a PEG ratio of 3.19 and a beta of 0.41. The company has a debt-to-equity ratio of 5.04, a current ratio of 1.03 and a quick ratio of 0.63. The firm has a 50 day simple moving average of $160.25 and a 200 day simple moving average of $145.43. The Clorox Company has a one year low of $114.68 and a one year high of $169.09.

Clorox (NYSE:CLX) last issued its quarterly earnings data on Thursday, August 1st. The company reported $1.82 EPS for the quarter, beating the consensus estimate of $1.54 by $0.28. The business had revenue of $1.90 billion during the quarter, compared to the consensus estimate of $1.97 billion. Clorox had a net margin of 3.95% and a return on equity of 281.12%. Research analysts predict that The Clorox Company will post 6.64 earnings per share for the current fiscal year.

Clorox Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, November 7th. Shareholders of record on Wednesday, October 23rd will be given a $1.22 dividend. This represents a $4.88 annualized dividend and a yield of 3.07%. The ex-dividend date of this dividend is Wednesday, October 23rd. Clorox’s dividend payout ratio (DPR) is currently 252.85%.

Insider Buying and Selling at Clorox

In other Clorox news, EVP Angela C. Hilt sold 1,733 shares of the company’s stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $165.52, for a total value of $286,846.16. Following the completion of the transaction, the executive vice president now directly owns 13,471 shares in the company, valued at approximately $2,229,719.92. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 0.51% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have issued reports on CLX shares. Evercore ISI cut their price objective on shares of Clorox from $140.00 to $139.00 and set an “underperform” rating for the company in a report on Monday, October 14th. Citigroup boosted their price objective on shares of Clorox from $165.00 to $170.00 and gave the company a “neutral” rating in a report on Friday, September 6th. TD Cowen began coverage on shares of Clorox in a report on Tuesday, July 23rd. They issued a “sell” rating and a $122.00 price objective for the company. DA Davidson reaffirmed a “neutral” rating and set a $153.00 price target on shares of Clorox in a report on Friday, September 6th. Finally, JPMorgan Chase & Co. upped their price target on shares of Clorox from $148.00 to $174.00 and gave the stock a “neutral” rating in a report on Friday, October 11th. Six equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and one has given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $150.14.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.